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ABSTRACT: Although it is an important approach in breast 
cancer treatment, curative-intent surgery carries a risk of 
being paradoxically favorable for tumor progression. Since 
local anesthetic technique is hypothesized as a therapeutic 
opportunity to reduce neoplastic maintenance and dispersal, we 
aim to evaluate its effect on breast cancer-related outcomes in 
the clinical setting. This is a systematic review of the literature 
that searched for articles in PubMed database using MeSH 
descriptors: “mastectomy”, “mastectomy, radical”, “anesthesia, 
local”, “recurrence”, “neoplasm recurrence, local”. We selected 
six articles, and the majority of those had a retrospective design, 
and only one was a randomized controlled trial. Among discussed 
differences in variables analysis, inclusion criteria and evaluated 
endpoints, five studies did not present appreciable effect of 
local anesthetic technique on breast-cancer related outcomes. 
Thus, although local anesthesia has potential benefits in long-
term cancer recurrence and overall survival, this review did not 
find enough clinical evidence to support this intervention as a 
standard of practice for such purpose. However, it may reduce 
intraoperative opioid consumption and provide a feasible option 
for pain management, that could improve patient’s health-related 
quality of life.
Keywords: Breast neoplasms; Mastectomy; Anesthetics, Local; 
Neoplasm recurrence; Survival.
RESUMO: Apesar de ser uma importante abordagem para o 
tratamento do câncer de mama, a cirurgia pode paradoxalmente 
favorecer a progressão tumoral, apesar da intenção curativa. 
Como as técnicas de anestesia local podem ser uma oportunidade 
terapêutica para reduzir a manutenção e dispersão neoplásica, o 
objetivo do estudo foi avaliar seus efeitos no comportamento 
evolutivo do câncer de mama no contexto clínico. Trata-se de uma 
revisão sistemática de literatura a partir da base de dados PubMed 
com os descritores MeSH “mastectomy”, “mastectomy, radical”, 
“anesthesia, local”, “recurrence”, “neoplasm recurrence, local”. 
Foram selecionados seis artigos, sendo a maioria retrospectivo e 
apenas um estudo controlado randomizado. Entre as diferenças 
discutidas na análise de variáveis, critérios de inclusão e resultados 
observados, cinco estudos não apresentaram efeito sobre o 
comportamento evolutivo do câncer de mama. Assim, apesar dos 
potenciais benefícios da anestesia local sobre o comportamento 
evolutivo do câncer de mama, essa revisão não encontrou 
evidência suficiente para apoiar essa intervenção para a prática 
clínica. Apesar disso, pode reduzir o consumo de opioide e prover 
uma opção viável para o manejo da dor, que pode melhorar a 
qualidade de vida das pacientes.
Palavras-chave: Revisão sistemática; Câncer de mama; 
Mastectomia; Anestesia local.
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INTRODUCTION
Breast cancer is the most incident cancer in Brazil, except for nonmelanoma skin tumors, 
with estimated 66,280 new cases for the year of 20201. 
Worldwide, it is the most incident cancer in women, with 
estimated 2,100,000 cases and 627,000 deaths in 20182. 
When multidisciplinary, therapeutic approach of 
breast cancer increases survival rates and improves patient’s 
quality of life3. Although there are continuous advances in 
treatment options, surgery remains its main support4.
Surgical removal of the primary tumor occurs with 
the risk of dispersal of neoplastic cells into the blood and 
lymphatic systems, as well as the risk of permanence 
of residual neoplastic cells5. Despite curative intent, a 
combination of perioperative factors leads to a release of 
chemical mediators that may, paradoxically, be direct or 
indirectly associated with tumor progression6.
The surgical  stress stablishes a relat ive 
immunosuppression, since it activates the hypothalamic-
pituitary-adrenal axis and the sympathetic nervous system, 
releasing catecholamines, prostaglandins and growth 
factors. Prostaglandins and catecholamines may activate 
beta-2 adrenergic receptors and COX-2, contributing to 
metastasis establishment7. The cytokines release appears to 
inhibit cell immunity through NK cells, which are important 
to detect and destroy circulating tumor cells8. Furthermore, 
the surgical tissue trauma stimulates angiogenic factors, 
like VEGF and TGF, which may increase tumor viability5.
Local anesthetic technique, as paravertebral thoracic 
block, attenuates neuroendocrine response to surgical 
stress and may preserve perioperative immune function9. 
Given that surgical stress response seems to increase 
opportunities for cancer dissemination and metastasis, 
this anesthetic approach is hypothesized as beneficial to 
long-term prognosis10.  
Thereby, we conducted this systematic review to 
evaluate the effect of local anesthetic technique on breast 
cancer-related outcomes in the clinical setting.
METHOD
For this present review, the PubMed database 
was assessed through Mesh descriptors: “mastectomy”, 
“mastectomy, radical”, “anesthesia, local”, “recurrence”, 
“neoplasm recurrence, local”. Reviews, editorials and 
comments were excluded. The search provided 65 articles, 
from which 11 were potentially relevant. After integral 
analysis, 6 studies were selected (Figure 1).
           Figure 1. Flow-chart describing the manuscripts’ selection process 
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RESULTS
We found 6 articles, published from 200611 to 
201912, with total samples varying between 12911 and 210812 
patients. Of these studies, 4 were retrospective11,13,14,15, 
1 presented a retrospective reviewed of prospective 
database16, and only 1 was a multicenter randomized 
clinical trial12. The average observation time varied between 
28.813 to 7215 months, and 1 study was stopped after a 
preplanned futility boundary was crossed12.
Regarding statistical analysis, 5 articles11,12,14,15,16 
used Cox proportional hazards regression to obtain 
adjusted results for potential confounding variables that 
may have influenced the sample prognosis. Furthermore, 
2 retrospective studies14,15 used the Propensity Score 
Matching (PSM) to establish the samples in order to 
improve its compatibilities regarding the analyzed 
variables.










Outcomes Statistical measuresGA GA + TPVB
Exadaktylos et 
al., 200611 RT  79  50  32 RFS RFS (HR, 0.21 [95% IC, 0.06-0.71]; p=0.012)
Starnes-Ott et 
al., 201513 RT  193  165  28.8 RFS RFS (HR, 1.84 [95% CI, 0.34-10.08]; p=0.53)
Tsigonis et al., 
201614 RT 375* 375* 66
OS, DFS, 
LRR
OS (HR, 0.81 [95% CI, 0.59–1.10]; p=0.17)
DFS (HR, 0.91 [95% CI, 0.55– 1.76]; p=0.87), 
LRR (HR, 1.73 [95% CI, 0.83–3.63]; p=0.15).
Cata et al., 
201615 RT 198* 198*
69.6 (RFS), 
72 (OS) RFS, OS
RFS (HR, 1.60 [95% CI, 0.81–3.16]; p= 0.172)
OS (HR, 1.28 [95% CI, 0.55-3.01]; p=0.567) 
Karmakar et 
al., 201716 PT 58
56 (s-TPVB)
59 (c-TPVB) 60 LRR, OS
GA + s-TPVB LRR (HR, 1.11 [95% CI, 0.32-3.83]; p=0.88), 
GA + c-TPVB LRR (HR, 0.79 [95% CI, 0.21-2.96]; p=0.88)
GA + s-TPVB OS (HR, 2.57 [95% CI, 0.66-9.92]; p=0.15)
GA + c-TPVB OS (HR, 0.66 [95% CI, 0.11-3.97]; p=0.15)
Sessler et al., 
201912 RCT 1065 1043 36 LRR LRR (HR, 0.97 [95% CI, 0.74-1.28]; p=0.84)
GA: General Anesthesia; TPVB: Thoracic Paravertebral Block; RT: retrospective; RFS: recurrence-free survival; HR: hazard ratio; OS: overall survival; 
DFS: disease-free survival; LRR: local regional recurrence; PT: prospective; s-TPVB: single TPVB injection followed by 72h postoperative placebo 
infusion; c-TPVB: continuous TPVB infusion 72h after surgery; RCT: randomized controlled trial *Sample obtained after PSM.
The first study was published in 2006 by Exadaktylos 
et al.11, that provided a retrospective analysis of 129 patients 
with a palpable breast lesion who underwent a mastectomy 
with axillary clearance or simple complete mastectomy. 
Patients with screen-detected cancer and those having 
plastic or reconstructive surgery were excluded. It was 
found a rate of recurrence-free survival in the GA + TPVB 
and GA groups as, respectively, 94% (95% CI, 87-100) and 
82% (95% CI, 74-91) for 24 months, and 94% (95% CI, 
87-100) and 77% (95% CI, 68-87) for 36 months (p=0.012).
No significative differences between the patient 
features, surgical details or prognostic factors were 
reported. However, the Nottingham prognostic index (that 
involves tumor size, axillary lymph node involvement, 
and histological grade), used in this study, is not validated 
to measure recurrence and metastasis propension17. 
Furthermore, it did not consider obesity as a variable that 
may have influenced medical decision in using general 
anesthesia13, aside from being considered a potential risk 
factor for tumor recurrence18. However, the promising result 
stimulated further clinical studies. 
Starnes-Ott et al.13 selected stage 0-III breast cancer 
patients submitted to partial or radical mastectomy, with or 
without lymph node dissection. The groups significatively 
varied in body mass index (BMI), and those in the GA group 
had a higher BMI than the GA+TPVB group (p=0.001). 
Also, patients in the GA+TPVB group were in more 
advanced stages (II or III) than the control group (p=0.01), 
were more submitted to chemotherapy (p=0.02) and had 
slightly longer surgical procedures (p=0.01). In the average 
period of 28.8 months observation time, the recurrence rate 
in the GA group was 1.4 per 100 000 person-days, and in 
the GA+TPVB group it was 2.6 per 100 000 person-days. 
The small number of events did not permit the analysis 
through adjusted variables.
Tsigonis et al.14 retrospectively review a prospective 
database of women stage 0-III breast cancer, not submitted 
to neoadjuvant therapy or ‘flap’ reconstruction. Patients 
from the TPVB group were older and had smaller, low 
staged and more hormone receptor-positive tumors. After 
using PSM to make the groups more comparable, except for 
tumor stage (p=0.026), there was no statistical difference 
between the groups for the evaluated outcomes.
The retrospective analysis made by Cata et al.15 
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evaluated women submitted to mastectomy with or 
without axillary lymph node dissection for non-metastatic 
cancer. After adjustment of variables, the analysis did 
not associate TPVB with significant change in measured 
outcomes. However, there was a substantial reduction 
in the intraoperative consumption of opioid. While the 
GA group received 541.06 ± 498.07 μg, the GA + TPVB 
group received 122.8 ± 77.85 μg in fentanyl equivalents 
(p < 0.001).
The intraoperative opioids usage was also analyzed 
by Karmakar et al.16, that used the same cohort to also 
assess chronic pain and health-related quality of life19. It 
was included women ASA 1-3, aged less than 70 years 
old, submitted to mastectomy with lymph node dissection. 
Since chronic pain was also assessed, women with previous 
chronic diseases or history of chronic pain were excluded. 
The GA + TVPB group was divided in two: one received a 
single ropivacaine injection associated to the GA, followed 
by a continuous saline infusion in the post-operative period 
(s-TPVB), and other that received a continuous ropivacaine 
infusion in the 72h post-operative period (c-TPVB). The 
measured outcomes were not significative different among 
the 3 groups. However, the intraoperative opioid medication 
was higher in the GA group [1.5 (IQR=0-3) mg] when 
compared to s-TPVB [0 (IQR=0–1) mg] (p<0.001) and 
c-TPVB [0 (IQR=0-1) mg] (p=0.001) groups. 
 The authors also reported that there was no 
significant difference in the incidence or relative risk of 
chronic pain when TPVB is associated with GA. However, 
TPVB groups presented lower pain intensity (p<0.05), 
fewer signs and symptoms of chronic pain (p≤0.01), and 
a better physical and mental health when compared to the 
GA group19.
The only randomized clinical trial was realized 
by Sessler et al.12 at 13 hospitals, in Argentina, Austria, 
Germany, Ireland, New Zealand, Singapore, United States 
and China, country that accounted for 59% of the sample. 
Women under 85 years old, diagnosed with primary 
breast cancer, with or without lymph node involvement, 
scheduled for unilateral or bilateral mastectomy were 
randomized. Women with previous breast cancer surgery, 
inflammatory carcinoma, ASA ≥4, who were scheduled 
for free-flap reconstruction or had the anesthetic approach 
contraindicated were not included. Among the GA+TPVB 
group, there was 102 (10%) recurrences, compared to 111 
(10%) of the GA group (HR, 0.97 [95% CI, 0.74-1.28]; 
p=0.84). Incisional pain after six months was reported by 
442 (52%) of 856 patients from the GA+TPVB group and 
by 456 (52%) of 872 patients from the GA group; after 12 
months, it was reported by 239 (28%) of 854 patients from 
GA+TPVB group and by 232 (27%) of 852 patients from 
GA group (overall interim-adjusted odds ratio 1,00, 95% 
CI 0·85–1·17; p=0.99). This study did not show difference 
between the anesthetic groups in terms of cancer-outcomes 
and frequency and severity of persistent incisional breast 
pain.
DISCUSSION
The results of retrospective studies, as the majority 
of our selection, are conditioned to the accuracy and 
availability of the information. Also, the assessment 
of predetermined variables and results of interest may 
be influenced by unmeasured factors, that could be 
confounding. Examples as the consumption of beta-
blockers20 and non-steroidal anti-inflammatory drugs21, 
as well as postoperative wound complications22, are also 
studied as possible interfering factors for breast cancer-
related outcomes during the perioperative period and were 
not observed as variables in our selected studies.
Anesthetic agents could also have impact on tumor 
progression. Propofol, used in three clinical studies11,12,16, 
reduced in vitro expression of Neuroepithelial Cell 
Transforming Gene 1, NET1, that promotes the migration 
of breast adenocarcinoma cells lines23. In vivo, propofol 
maintained the activity of NK cells and avoided pulmonary 
metastasis in animal models with breast neoplastic cells24.
Although there is not an actual consensus in 
literature regarding the type, dosage and application site, 
the use of intraoperative opioids as adjuvant drug for pain 
management also seems to present immunomodulatory 
effects that may impact cancer-related outcomes. One 
laboratorial study using breast neoplastic cells indicated 
higher activity of NK and T helper cells in models that 
received propofol and paravertebral anesthesia when 
compared to general anesthesia with opioid analgesia25. 
Also, it is considered that thoracic paravertebral block 
reduces the administration of perioperative opioids26, as 
observed by Sessler et al.12, that indicated a reduction in 
intraoperative morphine consumption with a standardized 
absolute difference of 1.8 between GA and GA+TPVB 
groups.
TPVB is a feasible therapeutic approach to reduce 
postoperative pain in breast cancer treatment, becoming 
a relevant intervention to facilitate recovery, accelerate 
hospital discharge and reduce care costs after the surgery27, 
considering that chronic pain is a common complaint for 
these patients28. Both studies that assessed chronic pain12,19 
have not found reduction in chronic pain incidence, 
however, Karmakar et al.19 observed less pain intensity in 
the GA + TPVB group.
CONCLUSION
Although preclinical studies suggested potential 
benefits of local anesthesia to reduce cancer recurrence and 
improve overall survival, this review did not find enough 
clinical evidence to support thoracic paravertebral block 
for this purpose in breast cancer surgery. However, local 
anesthesia may impact the reduction of intraoperative 
opioid and support pain management in the postoperative 
period, potentially improving patient’s health-related 
quality of life.
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